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There is an error in **Table ** [1](#psp412386-tbl-0001){ref-type="table"}. In Column 2, in the 10th row under the "Interaction" section, the text should read "OATP1B3 inhibition" instead of "OATP1B1 inhibition".

###### 

Osimertinib PBPK model input parameters

  p                                                        Parameters and models                                                              Osimertinib                                           Source
  -------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------- -------------------
  Physiochemical properties                                Molecular weight                                                                   499.61                                                Experimental data
  Log P                                                    5.45                                                                               Experimental data                                     
  pKa                                                      Diprotic base                                                                      Experimental data                                     
                                                           pKa 1: 9.50                                                                                                                              
                                                           pKa 2: 4.44                                                                                                                              
  B/P ratio                                                1                                                                                  Experimental data                                     
  f~u,\ plasma~                                            0.0133                                                                             Estimated value                                       
  f~u,\ gut~                                               0.00132                                                                            Predicted by Simcyp                                   
  Dosage form                                              Film coated tablets, immediate release                                                                                                   
  Absorption                                               Absorption model                                                                   First order                                           
  f~a~                                                     0.82                                                                               User defined value, based on Dickinson *et al*.^5^    
  k~a~ (CV%)                                               0.24                                                                               Estimated value from Pop‐PK model Brown *et al*.^7^   
  *P* ~eff~,man                                            0.187 × 10^−4^ cm/s                                                                Estimated based on clinical data                      
  Distribution                                             Distribution model                                                                 Full PBPK                                             
  V~ss~ (L/kg)                                             6.497                                                                              Simcyp Predicted using method 2                       
  Elimination                                              Clearance type                                                                     Enzyme kinetics                                       
  CYP1A2 CL~int~ (μL/min/pmol of isoform)                  0.520                                                                              Retrograde approach                                   
  CYP2A6 CL~int~ (μL/min/pmol of isoform)                  1.749                                                                                                                                    
  CYP2C9 CL~int~ (μL/min/pmol of isoform)                  0.479                                                                                                                                    
  CYP2E1 CL~int~ (μL/min/pmol of isoform)                  0.111                                                                                                                                    
  CYP3A4 CL~int~ (μL/min/pmol of isoform)                  0.731                                                                                                                                    
  CYP3A5 CL~int~ (μL/min/pmol of isoform)                  0.210                                                                                                                                    
  Renal CL (L/h)                                           0.235                                                                                                                                    
  Interaction                                              CYP2C8 reversible inhibition Ki (μM)                                               11.4                                                  Experimental data
  CYP3A4/5 reversible inhibition Ki (μM)                   2.55                                                                               Experimental data                                     
  CYP3A4 time‐dependent inhibition Ki (μM)                 1090                                                                               Experimental data                                     
  CYP3A4 time‐dependent inhibition Kinact (hr^−1^)         3.70                                                                               Experimental data                                     
  CYP3A4/5 induction IC~50~ (μM)                           0.117                                                                              Experimental data                                     
  CYP3A4/5 induction E~max~ (fold)                         10.78                                                                              Experimental data                                     
  Fu~mic~                                                  0.0261                                                                             Experimental data                                     
  Fu~inc~                                                  1                                                                                  Optimized value based on sensitivity analysis         
  OATP1B1 inhibition Ki (μM)                               22                                                                                 Experimental data                                     
  OATP1B3 inhibition Ki (μM)                               52.5                                                                               Experimental data                                     
  BCRP inhibition Ki (μM)                                  2                                                                                  Experimental data                                     
  Population                                               Oncology patients based Cheeti *et al*.^6^                                                                                               
  Clinical data                                            D5160C00001 (NCT01802632): Tablet monotherapy data single and multiple dose data                                                         
  D5160C00012 (NCT02157883): DDI study with itraconazole                                                                                                                                            
  D5160C00013 (NCT02197247): DDI study with rifampicin                                                                                                                                              
  D5160C00014 (NCT02197234): DDI study with simvastatin                                                                                                                                             
  D5160C00019 (NCT02317016): DDI study with rosuvastatin                                                                                                                                            

BCRP, breast cancer resistance protein; CL, clearance; CL~int~, intrinsic clearance; DDI, drug‐drug interaction; E~max~, maximum effect; OATP, organic anion‐transporting polypeptide; PBPK, physiologically based pharmacokinetic; Pop‐PK, population pharmacokinetic; V~ss~, volume of distribution at steady state.
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